
|Articles|January 4, 2007
Repeated dosing of radiopharmaceutical found safe, effective in PCa patients with bone mets
Repeated doses of the targeted radiopharmaceutical samarium Sm-153 lexidronam injection (Quadramet) are a safe and effective treatment option in patients with painful bone metastases secondary to prostate cancer, according to a multicenter, phase IV study published recently in the online edition of Cancer.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Kristen Scarpato, MD, on combination strategies in BCG-naïve NMIBC
2
Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing
3
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
4
Amanda North, MD, recaps SWIU 2026 session on imposter syndrome
5






